Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Gregg Masters"'
Autor:
Katherine E. Lewis, Mark J. Selby, Gregg Masters, Jose Valle, Gennaro Dito, Wendy R. Curtis, Richard Garcia, Kathy A. Mink, Kimberly S. Waggie, Matthew S. Holdren, Joseph F. Grosso, Alan J. Korman, Maria Jure-Kunkel, Stacey R. Dillon
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Recent advances in cancer treatment with checkpoint blockade of receptors such as CTLA-4 and PD-1 have demonstrated that combinations of agents with complementary immunomodulatory effects have the potential to enhance antitumor activity as compared t
Externí odkaz:
https://doaj.org/article/54e3b8070e6e4ea1b4254c709405e4a3
Autor:
Jedd D. Wolchok, Maria Jure-Kunkel, Taha Merghoub, Neal Rosen, Jon M. Wigginton, Ashok Gupta, Jianda Yuan, Shachi Vyas, Ruth Ann Gordon, Valerie Russell, Shigehisa Kitano, Jessica Katz, Charlotte Ariyan, Christine A. Pratilas, Gregg Masters, Margaret K. Callahan
PDF file - 528K, Supplementary Figure 1. BMS908662 enhances human T cell activation in vitro in a concentration-dependent manner. Supplementary Figure 2. BMS908662 inhibits the growth of BRAF mutant tumor cells in vitro. Supplementary Figure 3. BMS90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65d397f69a2a94ebf9bc0580eab85d3d
https://doi.org/10.1158/2326-6066.22537045.v1
https://doi.org/10.1158/2326-6066.22537045.v1
Autor:
Jedd D. Wolchok, Maria Jure-Kunkel, Taha Merghoub, Neal Rosen, Jon M. Wigginton, Ashok Gupta, Jianda Yuan, Shachi Vyas, Ruth Ann Gordon, Valerie Russell, Shigehisa Kitano, Jessica Katz, Charlotte Ariyan, Christine A. Pratilas, Gregg Masters, Margaret K. Callahan
RAF inhibitors selectively block extracellular signal–regulated kinase (ERK) signaling in BRAF-mutant melanomas and have defined a genotype-guided approach to care for this disease. RAF inhibitors have the opposite effect in BRAF wild-type tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::347b0e505ed4a077c0e94936117300de
https://doi.org/10.1158/2326-6066.c.6548308.v1
https://doi.org/10.1158/2326-6066.c.6548308.v1
Autor:
Jordan Blum, Vanessa Spires, Gregg Masters, Christina Yu, Saskia Burm, Matt Hancock, Omar Jabado, Brandon Higgs, Alexander Muik, Kristina Nuermberger, Friederike Gieseke, Tahamtan Ahmadi, Kate Sasser, Ozlem Tureci, Maria Jure-Kunkel, Ugur Sahin, Mark Fereshteh, Nora Pencheva
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Vanessa M. Spires, Gregg Masters, Christina Yu, Matt Hancock, Monique N. Luijten, Alexander Muik, Kristina Nuermberger, Friederike Gieseke, Tahamtan Ahmadi, Özlem Türeci, Maria Jure-Kunkel, Ugur Sahin, Mark Fereshteh, Homer C. Adams, Jordan M. Blum
Publikováno v:
Cancer Research. 83:3281-3281
GEN1042 (DuoBody®-CD40x4-1BB) is an investigational, novel, agonistic, bispecific antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells for priming and (re-) activation of tumor-specific immune responses. We p
Autor:
Gregg Masters, Douglas Goldstein
Publikováno v:
Mhealth Innovation ISBN: 9781003192893
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::563d76f4777a89221e52f8a1bc128662
https://doi.org/10.4324/9781003192893-42
https://doi.org/10.4324/9781003192893-42
Autor:
Joseph F. Grosso, Stacey R. Dillon, Kimberly S Waggie, Wendy R Curtis, Gennaro Dito, Mark J. Selby, Jose Valle, Richard Garcia, Katherine E. Lewis, Alan J. Korman, Kathy A Mink, Gregg Masters, Matthew S. Holdren, Maria Jure-Kunkel
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Oncoimmunology
Oncoimmunology
Recent advances in cancer treatment with checkpoint blockade of receptors such as CTLA-4 and PD-1 have demonstrated that combinations of agents with complementary immunomodulatory effects have the potential to enhance antitumor activity as compared t
Autor:
Emel Girit, Rachel Humphrey, Francis Y. Lee, Gregg Masters, Gennaro Dito, Maria Jure-Kunkel, John T. Hunt
Publikováno v:
Cancer Immunology, Immunotherapy
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding agent, has proven to be an effective monotherapy for metastatic melanoma and has shown antitumor activity in trials when administered with other therapeutic agents. We hypothesized that
Autor:
Margaret K. Callahan, Neal Rosen, Jedd D. Wolchok, Jessica Katz, Charlotte E. Ariyan, Gregg Masters, Valerie Russell, Christine A. Pratilas, Shigehisa Kitano, Ashok Kumar Gupta, Jon M. Wigginton, Jianda Yuan, Shachi Vyas, Maria Jure-Kunkel, Taha Merghoub, Ruth Ann Gordon
Publikováno v:
Cancer immunology research. 2(1)
RAF inhibitors selectively block extracellular signal–regulated kinase (ERK) signaling in BRAF-mutant melanomas and have defined a genotype-guided approach to care for this disease. RAF inhibitors have the opposite effect in BRAF wild-type tumor ce
Publikováno v:
Cancer Research. 74:5016-5016
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Nivolumab (BMS-936558; MDX-1106; ONO-4538) is a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively prevents interaction